-
Non–Small Cell Lung Cancer Takes Center StageA trio of clinical trials at the AACR Annual Meeting spotlight new avenues for non-small cell lung cancer treatment.
by Brad Jones
-
Pembrolizumab Shows Further Promise for MelanomaIn a phase III clinical trial, pembrolizumab yielded a 75.4 percent recurrence-free survival rate after 12 months among patients whose stage III melanoma tumors had been fully resected.
by Brad Jones
-
Making Decisions About Breast SurgeryPatients who opt for breast reconstruction after mastectomy tend to overestimate how happy they will be with the results, while those who do not get reconstruction tend to underestimate their future satisfaction.
by Cici Zhang
-
A Better Way to Screen for Lynch Syndrome?Researchers say a next-generation sequencing test could improve screening in colorectal cancer patients for a hereditary syndrome that raises cancer risk. Some experts have concerns.
by Cheryl Platzman Weinstock
-
Forward Look
Treating Early-Stage Lung CancerEfforts are underway to define role of high-dose radiation.
by Stephen Ornes
-
Q&A
Keeping Options OpenResearch scientist Teresa Woodruff is determined to make fertility preservation accessible to more young adults and children with cancer.
by Delia O'Hara
-
Liver Cancer on the RiseLiver cancer incidence and death rates are increasing rapidly. Although there is no screening test for the disease, minimizing risk factors—hepatitis B and C, smoking, obesity and type 2 diabetes—could prevent many cases from developing.
by Sue Rochman
-
Survivor Profile
Family MattersAfter Shigeo Tsuruoka was diagnosed with stomach cancer, his family came together to help him. His daughter, Aki Smith, was by his side as he navigated treatment and recovery. Now she offers guidance to other stomach cancer patients and caregivers.
by Kate Yandell
-
Is 3-D Mammography Better?A study enrolling patients compares a newer form of digital mammography to conventional 2-D digital mammography.
by Marci A. Landsmann
-
When Cancer Survivors Get Another CancerPatients diagnosed with a second cancer may be unnecessarily excluded from clinical trials.
by Kate Yandell
A monoclonal antibody drug reduced the risk of smoldering myeloma progressing to multiple myeloma in patients at high risk for disease progression.
by Sandra Gordon
Immunotherapy Improves Survival in Bladder CancerNew research indicates that adding immunotherapy to muscle-invasive bladder cancer treatment can improve event-free and overall survival.
by Laura Gesualdi-Gilmore
Cancer Patients Who Quit Smoking, Even Years After Diagnosis, Live LongerFindings from a recent study support smoking cessation after diagnosis, with the most pronounced effect in those who received treatment within six months of diagnosis.
by Kyle Bagenstose
Delaying Treatment ResistanceAdding a CDK 4/6 inhibitor extends progression-free survival for people with metastatic HR-positive, HER2-positive breast cancer.
by Thomas Celona
-
AACR IO: Revolutionizing Treatment through ImmunotherapyThe AACR’s immuno-oncology meeting brings together the leading experts in immunotherapy to accelerate progress in cancer science and medicine.
-
A New Resource Provides a Sanctuary for Black TNBC PatientsThe Black TNBC Sanctuary was created to help Black women with triple-negative breast cancer get answers about their diagnosis and care.
Dr. Humberto M. Guiot: Targeting Pancreatic Cancer in a Community-Based Clinical Trial
